Indications and uses
Helps prevent sunburn. If used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun.
Andalou BB sheer tint with SPF-30
- Manufacturer
- Andalou naturals
- Effective date
- 2013-01-31
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:41:51
Label at a glance#
ProductAndalou BB sheer tint with SPF-30
Active ingredientZinc Oxide
Label structure10 sections
Dosage and administration
Daily, alone or under make-up. Apply liberally 15 minutes before sun exposure and as needed. Reapply at least every 2 hours. Use water resistant sunscreen if swimming or sweating. Sun Protection Measures . Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures incl...
Storage and handling
Protect the product in this container from excessive heat and direct sun.
Contacts and useful links#
Websitewww.andalou.com
www.Andalou.com
www.Andalou.comLabel contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active Ingredient
Zinc Oxide 20%
Purpose
Sunscreen
Uses
- Helps prevent sunburn.
- If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early skin aging caused by the sun.
Warnings
- For external use only.
OTC - DO NOT USE SECTION
- Do not use on damaged or broken skin.
OTC - WHEN USING SECTION
- When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
- Stop use and ask a doctor if rash or irritation develops and lasts.
Directions
- Daily, alone or under make-up.
- Apply liberally 15 minutes before sun exposure and as needed.
- Reapply at least every 2 hours.
- Use water resistant sunscreen if swimming or sweating.
- Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10am-2pm, wear long sleeve shirts, pants and sunglasses.
- Children under 6 months: ask a doctor.
Inactive Ingredients
Aloe Barbadensis Juice1, Simmondsia Chinensis (Jojoba) and Helianthus Annuus (Sunflower) Oils1, Sorbitan Stearate, Glyceryl Stearate, Fruit Stem Cell and BioActive 8 Berry Complex1, Caprylic/Capric Triglycerides, Hyaluronic Acid, Magnesium Ascorbyl Phosphate (Vitamin C), Cucumis Sativus (Cucumber) Extract1, Punica Granatum (Pomegranate) Oil1, Algae and Cucumis Melo (Melon) Extracts, Magnesium Sulfate, Aspalathus Linearis (Rooibos), Hibiscus Rosa-Sinensis and Camellia Sinensis (White Tea) Extracts1 2, Iron Oxide, Phenethyl Alcohol, Ethylhexylglycerin, Citrus Aurantium Dulcis (Orange) Oil1
Other Information
- Protect the product in this container from excessive heat and direct sun.
Questions
Call (888) 898-6955 or visit www.Andalou.com
PRINCIPAL DISPLAY PANEL - 58 mL Tube Carton
NEW
ANDALOU
Naturals
FRUIT STEM CELL SCIENCE
BB
All in One
BEAUTY BALM
Sheer Tint
with SPF 30
REGENERATING
FRUIT STEM CELLS
BRIGHTENING
FRUIT STEM CELLS
RENEW ■ REPAIR ■ REGENERATE
58 mL e 2 fl oz
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 55560-0102-1 | 2021-11-24 | C162847 | 48780-1 | 9855d018-eab0-cd31-e053-dbdaa90ab51a | Andalou BB sheer tint with SPF-30 |
| 55560-0102-1 | 2019-11-27 | C162847 | 48780-1 | 9855d018-eab0-cd31-e053-dbdaa90ab51a | Andalou BB sheer tint with SPF-30 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Zinc Oxide | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| Zinc Oxide | ACTIVE MOIETY | SOI2LOH54Z | 1 | |
| aloe vera leaf | INACTIVE INGREDIENT | ZY81Z83H0X | 1 | |
| ethylhexylglycerin | INACTIVE INGREDIENT | 147D247K3P | 1 | |
| glyceryl monostearate | INACTIVE INGREDIENT | 230OU9XXE4 | 1 | |
| helianthus annuus flowering top | INACTIVE INGREDIENT | BKJ0J3D1BP | 1 | |
| hyaluronate sodium | INACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| jojoba oil | INACTIVE INGREDIENT | 724GKU717M | 1 | |
| magnesium ascorbyl phosphate | INACTIVE INGREDIENT | 0R822556M5 | 1 | |
| magnesium sulfate | INACTIVE INGREDIENT | DE08037SAB | 1 | |
| medium-chain triglycerides | INACTIVE INGREDIENT | C9H2L21V7U | 1 | |
| orange oil | INACTIVE INGREDIENT | AKN3KSD11B | 1 | |
| phenylethyl alcohol | INACTIVE INGREDIENT | ML9LGA7468 | 1 | |
| pomegranate seed oil | INACTIVE INGREDIENT | 0UI45XV0T6 | 1 | |
| sorbitan monostearate | INACTIVE INGREDIENT | NVZ4I0H58X | 1 | |
| tocopherol | INACTIVE INGREDIENT | R0ZB2556P8 | 1 | |
| zinc gluconate | INACTIVE INGREDIENT | U6WSN5SQ1Z | 1 |
Products#
Every source-derived product name is available through these pages.
- Andalou BB sheer tint with SPF-30
- Zinc Oxide
- glyceryl monostearate
- pomegranate seed oil
- aloe vera leaf
- zinc gluconate
- medium-chain triglycerides
- sorbitan monostearate
- orange oil
- magnesium sulfate
- helianthus annuus flowering top
- jojoba oil
- tocopherol
- magnesium ascorbyl phosphate
- hyaluronate sodium
- phenylethyl alcohol
- ethylhexylglycerin
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 55560-0102 | 55560-0102-1 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| phenylethyl alcohol | PHENYLETHYL ALCOHOL | ML9LGA7468 | SPRAY, METERED / NASAL | 2 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | OINTMENT / TOPICAL | 20 %w/w | ||
| magnesium sulfate | MAGNESIUM SULFATE | DE08037SAB | SOAP / TOPICAL | 0.2 %w/w | ||
| magnesium sulfate | MAGNESIUM SULFATE | DE08037SAB | CAPSULE / ORAL | NA | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | AEROSOL, FOAM / TOPICAL | 3.27 %w/w | ||
| magnesium sulfate | MAGNESIUM SULFATE | DE08037SAB | TABLET, FILM COATED / ORAL | 14 mg | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | SUPPOSITORY / VAGINAL | NA | ||
| orange oil | ORANGE OIL, COLD PRESSED | AKN3KSD11B | ELIXIR / ORAL | 0.24 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 23 mg | ||
| hyaluronate sodium | HYALURONATE SODIUM | YSE9PPT4TH | LOTION / TOPICAL | 0.01 %w/w | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET / SUBLINGUAL | 1.23 mg | ||
| phenylethyl alcohol | PHENYLETHYL ALCOHOL | ML9LGA7468 | SUSPENSION / INTRAMUSCULAR | 5 mg | ||
| hyaluronate sodium | HYALURONATE SODIUM | YSE9PPT4TH | GEL / TOPICAL | 463 mg | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | CREAM / TOPICAL | 177 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LIQUID / TOPICAL | 1 %w/w | ||
| phenylethyl alcohol | PHENYLETHYL ALCOHOL | ML9LGA7468 | CREAM / VAGINAL | NA | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | POWDER / SUBLINGUAL | 2 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | AEROSOL, FOAM / TOPICAL | 10.87 %w/w | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | INJECTION, EMULSION / INTRAVENOUS | 1.1 %w/v | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE, EXTENDED RELEASE / ORAL | 32.4 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SUSPENSION / ORAL | 10170 mg | ||
| orange oil | ORANGE OIL, COLD PRESSED | AKN3KSD11B | SUSPENSION / ORAL | 1 mg | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | SUSPENSION / ORAL | 62.5 mg/5ml | ||
| hyaluronate sodium | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET / ORAL | 2 mg | ||
| orange oil | ORANGE OIL, COLD PRESSED | AKN3KSD11B | LIQUID / ORAL | 50 mg | ||
| phenylethyl alcohol | PHENYLETHYL ALCOHOL | ML9LGA7468 | SOLUTION / OPHTHALMIC | 0.25 %w/w | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | CREAM / TOPICAL | 3300 mg | ||
| tocopherol | TOCOPHEROL | R0ZB2556P8 | TABLET / ORAL | 0.08 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | OINTMENT / TOPICAL | 5 %w/w | ||
| hyaluronate sodium | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SPRAY, METERED / SUBLINGUAL | 110 mg | ||
| tocopherol | TOCOPHEROL | R0ZB2556P8 | INJECTION, EMULSION / INTRAVENOUS | 0.02 %w/v | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | TABLET / ORAL | 4 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | POWDER, FOR SUSPENSION / ORAL | 3390 mg/5ml | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CREAM / VAGINAL | 140 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, DELAYED RELEASE / ORAL | 6 mg | ||
| tocopherol | TOCOPHEROL | R0ZB2556P8 | CAPSULE / ORAL | NA | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | LOTION / TOPICAL | 7 %w/w | ||
| orange oil | ORANGE OIL, COLD PRESSED | AKN3KSD11B | POWDER, FOR SUSPENSION / ORAL | 4 mg | ||
| tocopherol | TOCOPHEROL | R0ZB2556P8 | CREAM / TOPICAL | NA | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| phenylethyl alcohol | PHENYLETHYL ALCOHOL | ML9LGA7468 | SOLUTION / AURICULAR (OTIC) | 0.25 %w/w | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | OINTMENT / TOPICAL | NA | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CAPSULE, DELAYED RELEASE / ORAL | 15 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | CREAM / TOPICAL | 836 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | AEROSOL, FOAM / VAGINAL | 3 %w/w | ||
| phenylethyl alcohol | PHENYLETHYL ALCOHOL | ML9LGA7468 | SUSPENSION / INTRA-ARTICULAR | 5 mg | ||
| magnesium sulfate | MAGNESIUM SULFATE | DE08037SAB | TABLET, EXTENDED RELEASE / ORAL | 4 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, EXTENDED RELEASE / ORAL | 529 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | TABLET, EXTENDED RELEASE / ORAL | 0.37 mg | ||
| tocopherol | TOCOPHEROL | R0ZB2556P8 | CAPSULE, COATED / ORAL | 0.25 mg | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | CREAM / VAGINAL | 100 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | GRANULE, FOR SUSPENSION / ORAL | 4 mg | ||
| medium-chain triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | CAPSULE / ORAL | 4771 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUPPOSITORY / RECTAL | 35 mg | ||
| glyceryl monostearate | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LOTION / TOPICAL | 177 mg | ||
| sorbitan monostearate | SORBITAN MONOSTEARATE | NVZ4I0H58X | LOTION / TOPICAL | 89 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ee208236-5d20-42e8-b866-e640d09a8de0 | f0394e59-16d6-4348-b769-1666dbfe196b | 2019-07-15 | Warnings | f0394e59-16d6-4348-b769-1666dbfe196b |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.